Cardiovascular Outcomes in Patients on Hemodialysis following Drug-Eluting versus Bare-Metal Coronary Stents

Table 2

Characteristics of patients after 2 : 1 propensity match.

	BMS % ()	DES % ()	Standardized differences
Females	32.09	32.09	0.00
Age	67.54	66.91	0.05
Blacks	5.97	6.34	−1.55
Hispanics	5.22	5.22	0.00
CAD	23.88	25.75	−4.31
Previous MI	39.55	42.16	−5.30
CABG	29.85	32.46	−5.63
PCI	17.16	17.91	−1.96
CHF	43.28	42.16	2.26
CHF-NYHA IV	18.66	17.54	2.90
PVD	40.30	42.91	−5.29
HLD	82.84	80.22	6.72
HTN	94.03	95.52	−6.69
CVD	31.34	26.87	9.84
Diabetes	57.46	57.46	0.00
LVEF < 30%	27.61	27.99	−0.83
Nonsmokers	13.43	14.18	−2.16
High-risk lesion	42.54	41.05	3.02
Commercial insurance	11.94	11.94	0.00
HMO insurance	17.91	15.67	5.98
Stable angina	8.21	9.70	−5.21
Unstable angina	22.39	23.51	−2.65
NSTEMI	32.09	34.70	−5.52
STEMI	12.69	9.70	9.45
Emergency PCI	14.93	12.69	6.47

BMS, bare-metal stent; DES, drug-eluting stent; CAD, coronary artery disease; MI, myocardial infarction; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; CHF, congestive heart failure; NYHA, New York Heart Association; PVD, peripheral vascular disease; HLD, hyperlipidemia; HTN, hypertension; CVD, cerebrovascular disease; LVEF, left ventricular ejection fraction; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction.